Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Launches Industry’s First Assay for Measuring Matriptase Activity - A sensitive, long wavelength fluorimetric assay kit for measuring the activity of Matriptase, a protease implicated in carcinogenesis, is now commercially available - AnaSpec.com
AnaSpec Launches Industry’s First Assay for Measuring Matriptase Activity

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2015/02/11 - A sensitive, long wavelength fluorimetric assay kit for measuring the activity of Matriptase, a protease implicated in carcinogenesis, is now commercially available - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AnaSpec is pleased to announce the launch of the first commercially available kit for measuring the activity of Matriptase, a protease implicated in carcinogenesis.

The SensoLyte® Rh110 Matriptase Assay Kit provides a convenient assay for screening of Matriptase inhibitors and activators or for continuous assay of Matriptase activity using a highly sensitive fluorogenic substrate. Upon Matriptase cleavage, this substrate generates the Rh110 (Rhodamine 110) fluorophore which has a bright green fluorescence and can be detected at excitation/emission=496 nm/520 nm. The longer wavelength spectra and higher extinction coefficient of Rh110 provide greater sensitivity and less interference from other reaction components. This assay can detect as low as 0.15 ng/mL active Matriptase.

Matriptase (also known as MT-SP1, ST14, TADG-15 and epithin) is a trypsin-like protease from the family of type II transmembrane serine proteases. The spectrum of known Matriptase substrates includes extracellular matrix proteins, cell adhesion molecules, ion channels, growth-factor-like proteins and other proteases. Its actions can result in protein processing, activation or degradation. Matriptase is widely expressed in virtually all epithelium and is specifically found in tumors of epithelial origin. Matriptase has been implicated in carcinogenesis including ovarian, prostate and cervical cancers and is considered a drug target for developing cancer therapeutic agent (1-3).

Reference
1. Welman, A. et al. PLOS One 7, e34182 (2012).
2. List, K. et al. Mol Med 12, 1-3 (2006).
3. Quimbar, P. et al. J Biol Chem 288, 13885 (2013).

About AnaSpec

AnaSpec (anaspec.com), EGT Group is a leading provider of integrated proteomics and genomics solutions™ for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and Takyon™ qPCR MasterMixes. We carry a broad product line of biochemicals and reagents for basic research, high-throughput screening (HTS) and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Launches Industry’s First Assay for Measuring Matriptase Activity

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Cecilia Po - AnaSpec.com 
510-791-9560 cecilia[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems
Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan
Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.







 
  ©2005-2025 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today